# ISoOR 2026 Organoid Clinical Transformation Summit convened in Hangzhou

- Link: https://www.thailand-business-news.com/pr-news/isoor-2026-organoid-clinical-transformation-summit-convened-in-hangzhou
- Published: 2026-08-20T12:08:00+07:00
- Author: PR Newswire

ICORE launched; nine companies joined as founding members

HANGZHOU, China, Aug. 20, 2026 /PRNewswire/ — On August 18, the International Society
of Organoid Research (ISoOR) held its 2026 Organoid Clinical Transformation Summit
in Hangzhou. Under the theme "From Biological Models to Credible Evidence — Standardization
and Clinical Practice of Organoids," the event brought together leaders from academia,
clinical medicine, industry and investment to advance standardization and high-quality
development across the organoid field.

 [](https://mmx.prnasia.com/media/MS1972789/20260819224939EDT_image_1.jpg?id=OA2899396&p=medium600)

As organoids move into drug discovery, precision medicine and clinical translation,
the field is shifting from model construction to evidence generation. Stability,
reproducibility and methodologically validated data are becoming essential for broader
adoption. China’s recent inclusion of tumour organoid culture and drug-sensitivity
testing in its national medical-service pricing framework provides further policy
support for standardized clinical use.

ISoOR Chairman Prof. Peter E. Lobie opened the summit with a welcoming speech. Forum
speakers then shared latest advances and trends in tumor organoid drug-sensitivity
testing, thyroid and ophthalmic applications, drug development, automation, and 
internationally aligned biobanking standards.

Prof. Wu Lijuan from PLA Western Theater Command General Hospital emphasized that
consistent standards are essential for the broader adoption of organoid technology
in precision oncology and, ultimately, for translating its clinical potential into
benefits for more patients.

Prof. Shen Chongyang from Chengdu University of TCM discussed recent international
policy developments concerning New Approach Methodologies (NAMs). He predicted that,
if current progress continues, the first jointly validated NAMs that could be applied
in specific contexts without the need for repeated validation may emerge around 
2028.

A cross-sector roundtable moderated by Dr. Zhou Yi of AimingMed explored how research
institutions, clinicians, industry and investors can work together to move organoids
from scientific validation to clinical and commercial value.

The summit also marked the launch of International Center for Organoid Research 
and Enterprise (ICORE). Initiated by ISoOR, ICORE will support research, technical
validation, clinical translation, international collaboration and industry incubation.
Nine companies joined ICORE as its founding members. Drawing on its expertise in
organoid standardization and clinical translation, AimingMed will contribute to 
ICORE’s joint research and translational initiatives.

**About ISoOR**

The International Society of Organoid Research brings together academic, clinical
and industry resources to advance organoid standards, innovation and application.

**About AimingMed**

AimingMed is a medical technology company integrating organoid R&D, production, 
research services and clinical testing. Its portfolio includes the MasterAim® organoid
culture system, OSCAR-AI automation platform and organoid biobanks.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [ISoOR 2026 Organoid Clinical Transformation Summit convened in Hangzhou ](http://www.prnasia.com/story/archive/5030324_AE30324_0?rand=184833)